Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 497

1.

The Alopecia Areata Consensus of Experts (ACE) Study: Results of an International Expert Opinion on Treatments for Alopecia Areata.

Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, Bergfeld WF, Betz RC, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Donovan J, Eisman S, Farrant P, Green J, Grimalt R, Harries M, Hordinsky M, Irvine AD, Itami S, Jolliffe V, King B, Lee WS, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Piraccini BM, Rakowska A, Reygagne P, Roberts JL, Rudnicka L, Shapiro J, Sharma P, Tosti A, Vogt A, Wade M, Yip L, Zlotogorski A, Sinclair R.

J Am Acad Dermatol. 2020 Mar 9. pii: S0190-9622(20)30375-3. doi: 10.1016/j.jaad.2020.03.004. [Epub ahead of print]

PMID:
32165196
2.

Can Clinical Genetics Laboratories be Sued for Medical Malpractice?

Foulkes AL, Roberts JL, Appelbaum PS, Chung WK, Clayton EW, Evans B, Marchant GE.

Ann Health Law Life Sci. 2020 Winter;29(1):153-172. No abstract available.

PMID:
32154515
3.

The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.

Roberts JL, Poklepovic A, Booth L, Dent P.

Cell Signal. 2020 Feb 19;70:109573. doi: 10.1016/j.cellsig.2020.109573. [Epub ahead of print]

PMID:
32087304
4.

When health tech companies change their terms of service.

Roberts JL, Hawkins J.

Science. 2020 Feb 14;367(6479):745-746. doi: 10.1126/science.aaz6732. No abstract available.

PMID:
32054751
5.

Fingolimod Augments Monomethylfumarate Killing of GBM Cells.

Dent P, Booth L, Roberts JL, Poklepovic A, Hancock JF.

Front Oncol. 2020 Jan 28;10:22. doi: 10.3389/fonc.2020.00022. eCollection 2020.

6.

(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.

Dent P, Booth L, Roberts JL, Poklepovic A, Hancock JF.

J Cell Physiol. 2020 Jan 27. doi: 10.1002/jcp.29580. [Epub ahead of print]

PMID:
31985048
7.

GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.

Booth L, Roberts JL, West C, Von Hoff D, Dent P.

J Cell Physiol. 2020 Jan 17. doi: 10.1002/jcp.29464. [Epub ahead of print]

PMID:
31951027
8.

Deletion of Wnt5a in osteoclasts results in bone loss through decreased bone formation.

Roberts JL, Liu G, Paglia DN, Kinter CW, Fernandes LM, Lorenzo J, Hansen MF, Arif A, Drissi H.

Ann N Y Acad Sci. 2020 Mar;1463(1):45-59. doi: 10.1111/nyas.14293. Epub 2020 Jan 9.

PMID:
31919867
9.

Deletion of Runx1 in osteoclasts impairs murine fracture healing through progressive woven bone loss and delayed cartilage remodeling.

Paglia DN, Diaz-Hernandez ME, Roberts JL, Kalinowski J, Lorenzo J, Drissi H.

J Orthop Res. 2019 Nov 26. doi: 10.1002/jor.24537. [Epub ahead of print]

PMID:
31769548
10.

Advances and Promises of Nutritional Influences on Natural Bone Repair.

Roberts JL, Drissi H.

J Orthop Res. 2020 Apr;38(4):695-707. doi: 10.1002/jor.24527. Epub 2019 Nov 26. Review.

PMID:
31729041
11.

Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology.

Roberts JL, Ghali F, Aganovic L, Bechis S, Healy K, Rivera-Sanfeliz G, Autorino R, Derweesh I.

Abdom Radiol (NY). 2019 Dec;44(12):3893-3905. doi: 10.1007/s00261-019-02293-9.

PMID:
31701194
12.

The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib.

Booth LA, Roberts JL, Dent P.

Semin Cancer Biol. 2019 Oct 20. pii: S1044-579X(19)30024-0. doi: 10.1016/j.semcancer.2019.10.013. [Epub ahead of print] Review.

PMID:
31644944
13.

Clinicopathologic and immunophenotypic characterization of lichen planopilaris and central centrifugal cicatricial alopecia: A comparative study of 51 cases.

Jordan CS, Chapman C, Kolivras A, Roberts JL, Thompson NB, Thompson CT.

J Cutan Pathol. 2020 Feb;47(2):128-134. doi: 10.1111/cup.13592. Epub 2019 Nov 25.

PMID:
31605498
14.

Veracity in the Review Process.

de Ru JA, Ward TN, Roberts JL.

Headache. 2019 Oct;59(9):1429-1433. doi: 10.1111/head.13671. No abstract available.

PMID:
31603555
15.

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2019 Aug 20;10(49):5120-5122. doi: 10.18632/oncotarget.27162. eCollection 2019 Aug 20.

16.

Editor's Note: Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs.

Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P.

Mol Cancer Ther. 2019 Sep;18(9):1669. doi: 10.1158/1535-7163.MCT-19-0666. No abstract available.

PMID:
31481480
17.

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.

Booth L, Roberts JL, Poklepovic A, Dent P.

Front Oncol. 2019 Jul 18;9:650. doi: 10.3389/fonc.2019.00650. eCollection 2019.

18.

Equine Calming Products: A Short Survey Into Their Use, Effect, and Knowledge Using a Small Sample of Horse Owners in the North of Scotland, UK.

Ross DJ, Roberts JL.

J Equine Vet Sci. 2018 Sep;68:63-67. doi: 10.1016/j.jevs.2018.05.208. Epub 2018 May 26.

PMID:
31256891
19.

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.

Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J, Hancock JF.

Oncogene. 2019 Jul;38(30):5890-5904. doi: 10.1038/s41388-019-0849-8. Epub 2019 Jun 28.

PMID:
31253872
20.

Forensic genealogy and the power of defaults.

Ram N, Roberts JL.

Nat Biotechnol. 2019 Jul;37(7):707-708. doi: 10.1038/s41587-019-0172-5. No abstract available.

PMID:
31189937
21.

A Nudge Toward Meaningful Choice.

Fowler LR, Roberts JL.

Am J Bioeth. 2019 May;19(5):76-78. doi: 10.1080/15265161.2019.1588413. No abstract available.

PMID:
31090530
22.

Peptoid microsphere coatings: The effects of helicity, temperature, pH, and ionic strength.

Perez Bakovic GR, Roberts JL, Colford B, Joyce M, Servoss SL.

Biopolymers. 2019 Jun;110(6):e23283. doi: 10.1002/bip.23283. Epub 2019 Apr 22.

PMID:
31009076
23.

Rural and Urban Differences in the Adoption of New Health Information and Medical Technologies.

Haggstrom DA, Lee JL, Dickinson SL, Kianersi S, Roberts JL, Teal E, Baker LB, Rawl SM.

J Rural Health. 2019 Mar;35(2):144-154. doi: 10.1111/jrh.12358. Epub 2019 Mar 4.

PMID:
30830983
24.

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

Booth L, Roberts JL, Poklepovic A, Dent P.

Oncol Signal. 2018 Jun;1(1):19-30. doi: 10.1016/j.onsig.2017.07.001. Epub 2017 Aug 16.

25.

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells.

Booth L, Roberts JL, Sander C, Lalani AS, Kirkwood JM, Hancock JF, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(5):700-710. doi: 10.1080/15384047.2018.1551747. Epub 2018 Dec 20.

26.

Racial and Socioeconomic Disparities in Cancer-Related Knowledge, Beliefs, and Behaviors in Indiana.

Rawl SM, Dickinson S, Lee JL, Roberts JL, Teal E, Baker LB, Kianersi S, Haggstrom DA.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):462-470. doi: 10.1158/1055-9965.EPI-18-0795. Epub 2018 Nov 28.

27.

Essential Steps to Ensure Publication in Headache (and Any Other Journal of Good Repute).

Roberts JL.

Headache. 2018 Nov;58(10):1501-1502. doi: 10.1111/head.13440. No abstract available.

PMID:
30481385
28.

Recovery planning towards doubling wild tiger Panthera tigris numbers: Detailing 18 recovery sites from across the range.

Harihar A, Chanchani P, Borah J, Crouthers RJ, Darman Y, Gray TNE, Mohamad S, Rawson BM, Rayan MD, Roberts JL, Steinmetz R, Sunarto S, Widodo FA, Anwar M, Bhatta SR, Chakravarthi JPP, Chang Y, Congdon G, Dave C, Dey S, Durairaj B, Fomenko P, Guleria H, Gupta M, Gurung G, Ittira B, Jena J, Kostyria A, Kumar K, Kumar V, Lhendup P, Liu P, Malla S, Maurya K, Moktan V, Van NDN, Parakkasi K, Phoonjampa R, Phumanee W, Singh AK, Stengel C, Subba SA, Thapa K, Thomas TC, Wong C, Baltzer M, Ghose D, Worah S, Vattakaven J.

PLoS One. 2018 Nov 8;13(11):e0207114. doi: 10.1371/journal.pone.0207114. eCollection 2018.

29.

Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.

Booth L, Roberts JL, Spiegel S, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(5):597-607. doi: 10.1080/15384047.2018.1538616. Epub 2018 Nov 2.

30.

Neratinib augments the lethality of [regorafenib + sildenafil].

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P.

J Cell Physiol. 2019 Apr;234(4):4874-4887. doi: 10.1002/jcp.27276. Epub 2018 Sep 10.

31.

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(2):157-168. doi: 10.1080/15384047.2018.1507665. Epub 2018 Sep 5.

32.

An ex-vivo model to determine dental pulp responses to heat and light-curing of dental restorative materials.

Lynch CD, Roberts JL, Al-Shehri A, Milward PJ, Sloan AJ.

J Dent. 2018 Dec;79:11-18. doi: 10.1016/j.jdent.2018.08.014. Epub 2018 Aug 31.

PMID:
30176259
33.

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.

Booth L, Roberts JL, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(1):109-121. doi: 10.1080/15384047.2018.1507258. Epub 2018 Aug 24.

34.

Mixed methods process evaluation of an enhanced community-based rehabilitation intervention for elderly patients with hip fracture.

Roberts JL, Pritchard AW, Williams M, Totton N, Morrison V, Din NU, Williams NH.

BMJ Open. 2018 Aug 8;8(8):e021486. doi: 10.1136/bmjopen-2018-021486.

35.

Valproate augments Niraparib killing of tumor cells.

Booth L, Roberts JL, Rais R, Poklepovic A, Dent P.

Cancer Biol Ther. 2018;19(9):797-808. doi: 10.1080/15384047.2018.1472190. Epub 2018 Aug 1.

36.

Hip fracture in the elderly multidisciplinary rehabilitation (FEMuR) feasibility study: testing the use of routinely collected data for future health economic evaluations.

Williams NH, Mawdesley K, Roberts JL, Din NU, Totton N, Charles JM, Hoare Z, Edwards RT.

Pilot Feasibility Stud. 2018 May 7;4:76. doi: 10.1186/s40814-018-0269-5. eCollection 2018.

37.

Preferences of older patients regarding hip fracture rehabilitation service configuration: A feasibility discrete choice experiment.

Charles JM, Roberts JL, Ud Din N, Williams NH, Yeo ST, Edwards RT.

J Rehabil Med. 2018 Jul 17;50(7):636-642. doi: 10.2340/16501977-2350.

38.

Enterococcus faecalis Demonstrates Pathogenicity through Increased Attachment in an Ex Vivo Polymicrobial Pulpal Infection.

Nishio Ayre W, Melling G, Cuveillier C, Natarajan M, Roberts JL, Marsh LL, Lynch CD, Maillard JY, Denyer SP, Sloan AJ.

Infect Immun. 2018 Apr 23;86(5). pii: e00871-17. doi: 10.1128/IAI.00871-17. Print 2018 May.

39.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Oncotarget. 2017 Dec 26;9(5):6062-6074. doi: 10.18632/oncotarget.23681. eCollection 2018 Jan 19.

40.

Transcriptional Mechanisms of Secondary Fracture Healing.

Roberts JL, Paglia DN, Drissi H.

Curr Osteoporos Rep. 2018 Apr;16(2):146-154. doi: 10.1007/s11914-018-0429-9. Review.

41.

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

Booth L, Roberts JL, Kirkwood J, Poklepovic A, Dent P.

Adv Cancer Res. 2018;137:1-15. doi: 10.1016/bs.acr.2017.11.004. Epub 2018 Jan 3. Review.

42.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 3;19(6):525-533. doi: 10.1080/15384047.2018.1436024. Epub 2018 Mar 6.

43.

TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition.

Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang HG, Dent P, Milstien S, Booth L, Spiegel S.

Autophagy. 2018;14(6):942-957. doi: 10.1080/15548627.2018.1429875. Epub 2018 Mar 11.

44.

Observation of a strong-coupling effect on electron-ion collisions in ultracold plasmas.

Chen WT, Witte C, Roberts JL.

Phys Rev E. 2017 Jul;96(1-1):013203. doi: 10.1103/PhysRevE.96.013203. Epub 2017 Jul 7.

PMID:
29347164
45.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Mar 4;19(3):239-247. doi: 10.1080/15384047.2018.1423927. Epub 2018 Jan 22.

46.

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.

Roberts JL, Poklepovic A, Booth L.

Oncotarget. 2017 Aug 2;8(59):99451-99469. doi: 10.18632/oncotarget.19807. eCollection 2017 Nov 21.

47.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P.

Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.

48.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2017 Oct 9;8(52):90262-90277. doi: 10.18632/oncotarget.21660. eCollection 2017 Oct 27. Erratum in: Oncotarget. 2019 Aug 20;10(49):5120-5122.

49.

HDAC inhibitors enhance the immunotherapy response of melanoma cells.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P.

Oncotarget. 2017 May 17;8(47):83155-83170. doi: 10.18632/oncotarget.17950. eCollection 2017 Oct 10.

50.

Development of an evidence-based complex intervention for community rehabilitation of patients with hip fracture using realist review, survey and focus groups.

Roberts JL, Din NU, Williams M, Hawkes CA, Charles JM, Hoare Z, Morrison V, Alexander S, Lemmey A, Sackley C, Logan P, Wilkinson C, Rycroft-Malone J, Williams NH.

BMJ Open. 2017 Oct 11;7(10):e014362. doi: 10.1136/bmjopen-2016-014362.

Supplemental Content

Loading ...
Support Center